Business
Aardvark is a clinical-stage biopharmaceutical company developing small-molecule therapies that activate innate homeostatic pathways for metabolic diseases.
Aardvark funded its pipeline with an IPO, but losses and cash burn expanded while key trials paused.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage metabolic disease biotechNote
- Revenue — No product revenue in local bundleNote
- Profitability — Net loss widened to $57.6MWatch
- Cash burn — Free cash flow was -$54.3MWatch
- Balance sheet — Equity improved to $106.6M after IPOOK
- Insiders — 7 buys / 0 sells; $388K boughtOK
- Accounting — No forensic screen in local bundleNote
Leadership changes
From Aardvark Therapeutics, Inc.'s own filings, the day they're filed.
- Nelson Sun · Chief Operating Officer · appointmenteff. 2026-02-09
- Bryan Jones · Chief Operating Officer · departureeff. 2026-02-09
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- DEF 14A · Annual proxy (pay & governance)2026-07-10
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aardvark Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.